13576-85-7 Usage
Description
(4-Methoxyphenethyl)urea is a chemical compound with the molecular formula C9H12N2O2, belonging to the class of urea derivatives. It features a methoxyphenethyl group attached to the urea moiety, which may contribute to its potential biological activities.
Uses
Used in Medicinal Chemistry:
(4-Methoxyphenethyl)urea is used as a compound with potential applications in medicinal chemistry due to its urea derivative nature. Urea derivatives are known for their diverse biological activities, which include anticancer, antiviral, and antimicrobial properties. The specific properties and potential uses of (4-Methoxyphenethyl)urea would need to be determined through further research and testing.
Note: Since the provided materials do not specify different industries for the applications, the usage is generalized under the category of "Medicinal Chemistry." If further information on specific industries is available, the applications can be listed accordingly.
Check Digit Verification of cas no
The CAS Registry Mumber 13576-85-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,5,7 and 6 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13576-85:
(7*1)+(6*3)+(5*5)+(4*7)+(3*6)+(2*8)+(1*5)=117
117 % 10 = 7
So 13576-85-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N2O2/c1-14-9-4-2-8(3-5-9)6-7-12-10(11)13/h2-5H,6-7H2,1H3,(H3,11,12,13)
13576-85-7Relevant articles and documents
Synthesis and Evaluation of 3,4-Dihydropyrimidin-2(1H)-ones as Sodium Iodide Symporter Inhibitors
Lacotte, Pierre,Puente, Celine,Ambroise, Yves
supporting information, p. 104 - 111 (2013/03/28)
The sodium iodide symporter (NIS) is responsible for the accumulation of iodide in the thyroid gland. This transport process is involved in numerous thyroid dysfunctions and is the basis for human contamination in the case of exposure to radioactive iodine species. 4-Aryl-3,4-dihydropyrimidin-2(1H)-ones were recently discovered by high-throughput screening as the first NIS inhibitors. Described herein are the synthesis and evaluation of 115 derivatives with structural modifications at five key positions on the pyrimidone core. This study provides extensive structure-activity relationships for this new class of inhibitors that will serve as a basis for further development of compounds with invivo efficacy and adequate pharmacokinetic properties. In addition, the SAR investigation provided a more potent compound, which exhibits an IC50 value of 3.2nM in a rat thyroid cell line (FRTL5).
